研究单位：[1]Jiangsu HengRui Medicine Co., Ltd.[2]Anhui Provincial Hospital,Hefei,Anhui,China,230001[3]Peking University Cancer Hospital & Institute-Department of Gastrointestinal Oncology,Beijing,Beijing,China,100142[4]The First Affiliated Hospital of Chongqing Medical University,Chongqing,Chongqing,China,400016[5]Guangxi Medical University Affiliated Tumor Hospital,Nanning,Guangxi,China,530021[6]The Fourth Hospital of Hebei Medical University,Shijiazhuang,Hebei,China,050000[7]Harbin Medical University Cancer Hospital-The Eighth Department of Internal Medicine,Harbin,Heilongjiang,China[8]Henan Cancer Hospital,Zhengzhou,Henan,China,450003[9]The First Affiliated Hospital of Zhengzhou University-Department of Medical Oncology,Zhengzhou,Henan,China,450052[10]Hubei Cancer Hospital-Department of Abdominal Oncology,Wuhan,Hubei,China,430079[11]Hunan Cancer Hospital,Changsha,Hunan,China,410031[12]The First Affiliated Hospital of Nanchang University,Nanchang,Jiangxi,China,330006[13]The Second Affiliated Hospital of Nanchang University,Nanchang,Jiangxi,China,330200[14]Shanxi Provincial Cancer Hospital-Gastroenterology Department,Taiyuan,Shanxi,China,030013[15]The First Affiliated Hospital of Xi''an Jiaotong University,Xi''an,Shanxi,China,710061[16]Tianjin Medical University Cancer Institute and Hospital-Department of digestive oncology,Tianjin,Tianjin,China,300060
研究目的：
The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A1811 combined with other antitumor therapies in advanced solid tumors. To explore the reasonable dosage of SHR-A1811 combined with other antitumor therapies for advanced solid tumors.
